The Moving Average Convergence Divergence (MACD) for IMVT turned positive on November 28, 2023. Looking at past instances where IMVT's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on November 24, 2023. You may want to consider a long position or call options on IMVT as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
IMVT moved above its 50-day moving average on November 24, 2023 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IMVT broke above its upper Bollinger Band on November 28, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMVT entered a downward trend on November 20, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.704) is normal, around the industry mean (20.645). P/E Ratio (0.000) is within average values for comparable stocks, (137.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.397).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases.
|ETFs / NAME||Price $||Chg $||Chg %|
|FT Cboe Vest Nasdaq-100 Buffer ETF – Dec|
|Innovator S&P 500 Ultra Buffer ETF™ Mar|
|First Trust S-Network Glb E-Com ETF|
|FlexShares Mstar DevMks exUS FctTilt ETF|
|iShares Global Tech ETF|
A.I.dvisor indicates that over the last year, IMVT has been closely correlated with SLNO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if IMVT jumps, then SLNO could also see price increases.